MA
Therapeutic Areas
Prime Medicine Pipeline
| Drug | Indication | Phase |
|---|---|---|
| PM359 | Chronic Granulomatous Disease (CGD) | Phase 1/2 |
| PM446 | Glycogen Storage Disease Type 1b (GSD1b) | Phase 1/2 |
| Undisclosed (Liver) | Wilson Disease | Preclinical |
| Undisclosed (Eye) | Retinitis Pigmentosa (CEP290-related) | Preclinical |
Leadership Team at Prime Medicine
AR
Allan Reine
Chief Executive Officer
AL
Ann Lee
Chief Technical Officer
MH
Matthew Hawryluk
Chief Business Officer
RB
Ryan Brown
Chief Legal Officer
NA
Niamh Alix
Chief Human Resources Officer
DL
David Liu
Scientific Co-Founder
AA
Andrew Anzalone
Scientific Co-Founder
JM
Jeff Marrazzo
Executive Chair of the Board